评估脊柱治疗的生物标志物试验(BEST)的设计与 rationale
Statistical Design and Rationale of the Biomarkers for Evaluating Spine Treatments (BEST) Trial
摘要 Abstract
慢性下腰痛(cLBP)是一种普遍存在的疾病,对功能和生活质量有深远影响。尽管存在多种基于证据的治疗方法,但它们的平均治疗效果都较为有限,这可能与个体间治疗反应的差异以及cLBP多样化的病因有关。这项多中心序贯、多次分配随机对照试验(SMART)研究了四种治疗模式,并通过两阶段随机化设计,旨在招募630名完成试验方案的受试者。主要目标是通过估计患者特征和初始治疗反应下的最优治疗或治疗组合,开发精准医学方法。分析策略集中于估计可解释的动态治疗方案,并识别对特定干预措施最敏感的亚组。为了增强通用性和招募规模,实施了广泛的纳入标准,特别是即使受试者无法被分配到其中一项(但不超过一项)研究干预措施时,也可以符合条件参与试验。在限制受试者可接受治疗的情况下进行招募,需要对标准的最小化方法进行修改以平衡协变量。BEST试验代表了迄今为止专注于临床决策的最大型SMART之一,也是针对cLBP最大的试验。通过收集大量的生物标志物和表型数据,该试验可能揭示潜在的治疗机制,并为临床实践中个性化治疗cLBP建立更基于证据的方法。
Chronic low back pain (cLBP) is a prevalent condition with profound impacts on functioning and quality of life. While multiple evidence-based treatments exist, they all have modest average treatment effects$\unicode{x2013}$potentially due to individual variation in treatment response and the diverse etiologies of cLBP. This multi-site sequential, multiple-assignment randomized trial (SMART) investigated four treatment modalities with two stages of randomization and aimed to enroll 630 protocol completers. The primary objective was to develop a precision medicine approach by estimating optimal treatment or treatment combinations based on patient characteristics and initial treatment response. The analysis strategy focuses on estimating interpretable dynamic treatment regimes and identifying subgroups most responsive to specific interventions. Broad eligibility criteria were implemented to enhance generalizability and recruitment, most notably that participants could be eligible to enroll even if they could not be assigned to one (but no more) of the study interventions. Enrolling participants with restrictions on the treatment they could be assigned necessitated modifications to standard minimization methods for balancing covariates. The BEST trial represents one of the largest SMARTs focused on clinical decision-making to date and the largest in cLBP. By collecting an extensive array of biomarker and phenotypic measures, this trial may identify potential treatment mechanisms and establish a more evidence-based approach to individualizing cLBP treatment in clinical practice.